Abstract

This study aimed to investigate the effects of two commercially available fish oils (FOs) containing different proportions of two omega-3 fatty acids (FA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), on the metabolic and endocrine dysfunctions of white adipose tissue resulting from obesity. Male C57BL/6J mice, 8 weeks old, received a control or high-fat diet (CO and HF groups, with 9% and 59% energy from fat, respectively) for 8 weeks. The next 8 weeks, the HF group was subdivided into HF, HF+FO/E (HF+5:1 EPA:DHA), and HF+FO/D (HF+5:1 DHA:EPA). Supplementation was performed by gavage, three times a week. All groups that received the HF diet had lower food and caloric intake, but a higher fat intake, body weight (BW) gain, glucose intolerance, and a significant increase in inguinal (ING), retroperitoneal (RP), and epididymal (EPI) adipose tissues when compared to the CO group. Additionally, HF and HF+FO/D groups showed insulin resistance, adipocyte hypertrophy, increased lipolysis and secretion of TNF-α, resistin and IL-10 adipokines by ING and RP adipocytes, and adiponectin only by the HF+FO/D group in ING adipocytes. All of these effects were completely reversed in the HF+FO/E group, which also showed partial reversion in BW gain and glucose intolerance. Both the HF+FO/E and HF+FO/D groups showed a reduction in ING and RP adipose depots when compared to the HF group, but only HF+FO/E in the EPI depot. HF+FO/E, but not HF+FO/D, was able to prevent the changes triggered by obesity in TNF-α, Il-10, and resistin secretion in ING and RP depots. These results strongly suggest that different EPA:DHA ratios have different impacts on the adipose tissue metabolism, FO being rich in EPA, but not in DHA, and effective in reversing the changes induced by obesity.

Highlights

  • Obesity is triggered by the interaction of several components, such as genetic, metabolic, behavioral, and environmental factors

  • During the second period (9–16 weeks) the animals in the HF group were separated into three different groups: HF, HF+fish oils (FOs)/E (5:1 eicosapentaenoic acid (EPA):docosahexaenoic acid (DHA)) and HF+FO/D (5:1 DHA:EPA)

  • FO supplementation, containing a combination of EPA and DHA in different proportions, is an important dietary source for omega-3 intake and several studies have shown a potent action of FO in the treatment of obesity and comorbidities [9,16,17,18,19]

Read more

Summary

Introduction

Obesity is triggered by the interaction of several components, such as genetic, metabolic, behavioral, and environmental factors. The abnormal or excessive accumulation of fat results from the imbalance between consumption and expenditure of calories, impairing health. Such imbalance is characterized by a greater intake of foods that have a high content of fat, cholesterol, sugar, and salt, as well as an increase in the consumption of processed foods and a significant reduction in physical activity [3,4]. Several studies in humans have shown that omega-3 eicosapentaenoic acid (EPA 20:5) and docosahexaenoic acid (DHA 22:6) diet supplementation can alter the concentration of ARA, EPA, and DHA in blood cells. A supplementation with approximately 1:3 EPA:DHA ratio for 8 weeks reduces ARA and increases

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call